VISTA
V-domain Ig suppressor of T cell activation (VISTA)
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory immune checkpoints (ICs) that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and
adaptive anti-tumoral immune responses. VISTA is a transmembrane protein that plays a crucial role in the regulation of antitumor immunity. Therapeutic intervention that inhibits the VISTA pathway constitutes a new approach in the treatment of cancer.
References:
- [1]. Ait Boujmia OK. V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study. Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1057-1065.
- [2]. Hosseinkhani N, et al. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol. 2021 May 19;12:676181.
All Product Categories
-
VISTA Related Products (16)
Related Products (16)
- 1
-
Onvatilimab
0 ImagesSynonyms: JNJ-61610588; CI-8993; VSTB112Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.
-
Anti-Mouse VISTA Antibody (13F3)
0 ImagesCat. No.: HY-P990145Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF.
-
M351-0056
0 ImagesM351-0056 is an orally active VISTA agonist with a Kd value of 12.60 μM. M351-0056 inhibits the activation of the JAK2-STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2, and regulates type I interferon (IFN-I) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines (IFN-γ, IL-17A, TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod (HY-B0180)-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus.
-
Anti-VSIR/VISTA Antibody (SG7)
0 ImagesCat. No.: HY-P991447Purity: 98.07%Anti-VSIR/VISTA Antibody (SG7) is an antibody targeting VISTA, with a Kd of 0.14 nM for human VISTA and 1 nM for mouse VISTA. Anti-VSIR/VISTA Antibody (SG7) blocks the function of VISTA, prevents VISTA from binding to T cells, restores suppressed T cell activation, and blocks the interactions between VISTA and PSGL-1 as well as VSIG3. Anti-VSIR/VISTA Antibody (SG7) slows tumor growth, reduces PMN-MDSCs, and increases the numbers of CD4+ and CD8+ T cells in the tumor microenvironment. Anti-VSIR/VISTA Antibody (SG7) can be used in studies related to melanoma, colon cancer, and breast cancer.
-
Solnerstotug
0 ImagesSynonyms: SNS-101; SNA 101Solnerstotug (SNS-101; SNA 101) is a pH-sensitive humanized IgG1κ antibody targeting VISTA. The affinity of Solnerstotug for VISTA decreases continuously with increasing pH, with KD values of 0.35 nM and 353 nM at pH 5.8 and pH 7.4, respectively. Solnerstotug reshapes the tumor microenvironment by selectively blocking the interaction of VISTA with receptors such as PSGL-1 (IC50 = 6.7 nM) in acidic environments, polarizing macrophages toward a pro-inflammatory M1-like phenotype and increasing intratumoral CD8+ T cell infiltration. Solnerstotug can be used for cancer research.
-
HMBD-002
0 ImagesCat. No.: HY-P992369HMBD-002 is an Fc-independent, non-depleting IgG4 subclass antibody that targets VISTA and VSIG3. It is widely used in research related to various solid tumors, including colon cancer, triple-negative breast cancer, and non-small cell lung cancer. HMBD-002 blocks the interactions of VISTA with VSIG3 and LRIG1, relieves immunosuppression without depleting VISTA-positive cells, activates the cytotoxic program of CD8+ T cells, and drives the type I interferon signaling pathway. HMBD-002 reprograms tumor-associated macrophages to the M1 phenotype, reduces tumor infiltration of inhibitory myeloid cells, thereby significantly inhibiting tumor growth and improving survival. HMBD-002 is well tolerated in rodent and non-human primate animal models.
-
MS102
0 ImagesMS102 is an orally active ubiquitin specific peptidase 2 (USP2) inhibitor with an IC50 of 5.46 μM. MS102 has viable antiviral activity against ACE2-dependent coronaviruses. MS102 significantly reduces V-domain Ig suppressor of T cell activation (VISTA) protein abundance in vitro and in vivo. MS102 can be used for the study of SARS-CoV-2. MS102 can be used in combination with anti-PD-1 immunotherapy to enhance the anti-tumor immune response.
-
Anti-Mouse VISTA Antibody (8G8)
0 ImagesCat. No.: HY-P991776Purity: 98.26%Anti-Mouse VISTA Antibody (8G8) reacts with mouse VISTA. Anti-Mouse VISTA Antibody (8G8) is an agonistic antibody with immunosuppressive properties. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).
-
MG-V-53
0 ImagesCat. No.: HY-Q25865CAS No.: 920157-23-9MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity.
-
DOTA-Bn-CA-170
0 ImagesCat. No.: HY-P11253DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
-
PD-L1/VISTA-IN-1
0 ImagesCat. No.: HY-170793CAS No.: 2978623-09-3PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
-
W0180
0 ImagesCat. No.: HY-P991421
- 1
